ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company's products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP). Its second CTX stem cell candidate is for the treatment of critical limb ischaemia. The Company's exosomes nanomedicine platform focuses on generating early pre-clinical data in cancer. Its ReNcell Products include ReNcellVM and ReNcellCX cell lines. It is engaged in Phase II clinical trial of CTX cells for stroke disability. It is engaged in Phase I clinical trial of CTX cells for Critical Limb Ischaemia. It is engaged in Phase I clinical trial of hRPC stem cell candidate. The Company has completed pre-clinical trials CTX-derived exosomes.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: LON:RENE
- CUSIP: N/A
- Web: www.reneuron.com/
- Market Cap: £53.01 million
- Outstanding Shares: 3,164,618,000
- 50 Day Moving Avg: GBX 1.83
- 200 Day Moving Avg: GBX 2.01
- 52 Week Range: GBX 1.55 - GBX 3.68
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.000
- Annual Revenue: $899,999.00
- Price / Sales: 58.90
- Book Value: GBX 0.02 per share
- Price / Book: 0.99
- EBIDTA: ($18,130,000.00)
- Net Margins: -32,825.00%
- Return on Equity: -27.66%
- Return on Assets: -25.36%
- Average Volume: 3.01 million shs.
Frequently Asked Questions for ReNeuron Group Plc (LON:RENE)
What is ReNeuron Group Plc's stock symbol?
ReNeuron Group Plc trades on the London Stock Exchange (LON) under the ticker symbol "RENE."
Where is ReNeuron Group Plc's stock going? Where will ReNeuron Group Plc's stock price be in 2017?
2 brokerages have issued 12-month price targets for ReNeuron Group Plc's stock. Their forecasts range from GBX 9 to GBX 15. On average, they expect ReNeuron Group Plc's stock price to reach GBX 12 in the next year. View Analyst Ratings for ReNeuron Group Plc.
Who are some of ReNeuron Group Plc's key competitors?
Some companies that are related to ReNeuron Group Plc include Palatin Technologies (PTN), Eiger BioPharmaceuticals (EIGR), Tissue Regenix Group PLC (TRX), CASI Pharmaceuticals (CASI), aTyr Pharma (LIFE), ArQule (ARQL), Zynerba Pharmaceuticals (ZYNE), Vernalis plc (VER), Brainstorm Cell Therapeutics (BCLI), CytRx Corporation (CYTR), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Infinity Pharmaceuticals (INFI), Navidea Biopharmaceuticals (NAVB), Galectin Therapeutics (GALT), OvaScience (OVAS), Sunesis Pharmaceuticals (SNSS) and Fibrocell Science (FCSC).
Who are ReNeuron Group Plc's key executives?
ReNeuron Group Plc's management team includes the folowing people:
- Olav Hellebo, Chief Executive Officer, Director
- Michael Elliott Hunt, Chief Financial Officer, Executive Director, Company Secretary
- John D. Sinden Ph.D., Chief Scientific Officer, Executive Director
- Sharon Grimster, Vice President Development and General Manager, Wales
- Randolph Corteling, Head of Research
- Julian Howell, Chief Medical Officer
- Shaun Stapleton, Head - Regulatory Affairs
- John Edward Berriman, Non-Executive Chairman of the Board
- Simon Christopher Cartmell, Non-Executive Director
- Timothy Henry Corn, Non-Executive Director
How do I buy ReNeuron Group Plc stock?
Shares of ReNeuron Group Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is ReNeuron Group Plc's stock price today?
MarketBeat Community Rating for ReNeuron Group Plc (LON RENE)MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of ReNeuron Group Plc stock can currently be purchased for approximately GBX 1.68.
Consensus Ratings for ReNeuron Group Plc (LON:RENE) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||GBX 12|
Analysts' Ratings History for ReNeuron Group Plc (LON:RENE)
(Data available from 9/19/2015 forward)
|6/29/2017||N+1 Singer||Reiterated Rating||Buy|
|4/4/2017||Stifel Nicolaus||Reiterated Rating||Buy||GBX 15|
Earnings History for ReNeuron Group Plc (LON:RENE)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for ReNeuron Group Plc (LON:RENE)
Current Year EPS Consensus Estimate: $-0.730 EPS
Dividend History for ReNeuron Group Plc (LON:RENE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ReNeuron Group Plc (LON:RENE)Insider Trades by Quarter for ReNeuron Group Plc (LON:RENE)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/7/2017||Michael Hunt||Insider||Buy||250,000||GBX 3||£7,500|
|2/2/2016||Edward Berriman,John||Insider||Buy||318,476||GBX 3||£9,554.28|
|1/29/2015||Olav Hellebø||Insider||Buy||322,778||GBX 3.10||£10,006.12|
Headline Trends for ReNeuron Group Plc (LON:RENE)
Latest Headlines for ReNeuron Group Plc (LON:RENE)
ReNeuron Group Plc (RENE) Chart for Tuesday, September, 19, 2017